# Safety and Efficacy of LCI699 in Cushing's Disease Patients

Source: https://onco.cc/trials/nct01331239/  
OnCo record `nct01331239` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Osilodrostat in Pituitary tumours, run by Novartis Pharmaceuticals, completed.

## Summary

Safety and Efficacy of LCI699 in Cushing's Disease Patients is a phase 2 interventional study registered as NCT01331239 by Novartis Pharmaceuticals, with 31 participants recorded, started 2011-03-23 and reaching its primary completion in 2019-10-22. Interventions recorded: LCI699. Conditions recorded: Cushings Disease, Cushing Disease.

Linked to the drug Osilodrostat because the registry names it among its interventions and Pituitary tumours among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT01331239
- Phase: 2
- Setting: A Proof of Concept, Open-label, Forced Titration, Multi-center Study to Assess the Safety/Tolerability and Efficacy of 10-weeks Treatment of LCI699 in Patients With Cushing's Disease
- Sponsor: Novartis Pharmaceuticals
- Enrolled: 31

## Sources

- ClinicalTrials.gov NCT01331239: https://clinicaltrials.gov/study/NCT01331239

## Connected records

- cancers: [Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma](https://onco.cc/cancers/pituitary-tumours/)
- drugs: [Osilodrostat](https://onco.cc/drugs/osilodrostat/)

---
JSON: https://onco.cc/api/v1/entities/nct01331239.json